Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Kratom

Mark Sanderson and Adrianna Rowe
CMAJ October 07, 2019 191 (40) E1105; DOI: https://doi.org/10.1503/cmaj.190470
Mark Sanderson
Department of Emergency Medicine (Sanderson, Rowe), University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrianna Rowe
Department of Emergency Medicine (Sanderson, Rowe), University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Kratom (Mitragyna speciosa Korth.) is a herbal product from Southeast Asia with opioid agonist properties

Kratom is a herbal product that is most commonly obtained as a powder and consumed as a beverage.1–3 Kratom contains the indole alkaloid compounds mitragynine and 7-hydroxymitragynine, which are opioid receptors agonists.2,3 They reduce pain, cause dose-dependent stimulant and sedative effects, and have an adverse effect profile consistent with opioid activity.2 Kratom is not detected on conventional urine drug-screening tests.2

Kratom use is increasing

Avoidance of drug withdrawal, treatment of chronic pain and recreation are common reasons for kratom use.1,2 American poison centres saw an increase in kratom-related calls, from 18 exposures in 2011 to 357 in the first 7 months of 2018.4 The US Centers for Disease Control and Prevention identified 91 cases in which kratom was identified as a potential cause of death from July 2016 to December 2017.5

Effects of kratom use appear to be dose dependent

Kratom use is associated with stimulant effects at low doses (1–5 g), and sedative effects at higher doses (5–15 g).2 Negative adverse effects most commonly include gastrointestinal symptoms and agitation, and are reported to be dose dependent.1,4

Kratom users may experience withdrawal with cessation

Moderate to heavy daily users of kratom (≥ 3 doses/d) commonly have cravings and withdrawal symptoms similar to those of opioid withdrawal with cessation.2,5 Of kratom users, 43% reported negative adverse events if they abstained for more than 48 hours.1

Management of kratom ingestion is supportive

Doses in excess of 15 g may mimic an opioid toxidrome. Naloxone should be given for drowsiness and respiratory depression.3 Severe adverse events, including death, have been reported with kratom use in conjunction with opioids, benzodiazepines, modafinil and other medications.2,5 Supportive management and toxicology consultation are indicated for cases of overdose or intoxication.

Figure
Image courtesy of istock.com\tonaquatic

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Grundmann O
    . Patterns of kratom use and health impact in the US — results from an online survey. Drug Alcohol Depend 2017;176:63–70.
    OpenUrl
  2. ↵
    1. Warner ML,
    2. Kaufman NC,
    3. Grundmann O
    . The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med 2016;130:127–38.
    OpenUrl
  3. ↵
    1. Rosenbaum CD,
    2. Carreiro SP,
    3. Babu KM
    . Here today, gone tomorrow … and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8:15–32.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Eggleston W,
    2. Stoppacher R,
    3. Suen K,
    4. et al
    . Kratom use and toxicities in the United States. Pharmacotherapy 2019;39:775–7.
    OpenUrl
  5. ↵
    1. Olsen EO,
    2. O’Donnell J,
    3. Mattson CL,
    4. et al
    . Unintentional drug overdose deaths with kratom detected — 27 states, July 2016–December 2017. MMWR Morb Mortal Wkly Rep 2019;68:326–7.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (40)
CMAJ
Vol. 191, Issue 40
7 Oct 2019
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Kratom
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Kratom
Mark Sanderson, Adrianna Rowe
CMAJ Oct 2019, 191 (40) E1105; DOI: 10.1503/cmaj.190470

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Kratom
Mark Sanderson, Adrianna Rowe
CMAJ Oct 2019, 191 (40) E1105; DOI: 10.1503/cmaj.190470
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Kratom (Mitragyna speciosa Korth.) is a herbal product from Southeast Asia with opioid agonist properties
    • Kratom use is increasing
    • Effects of kratom use appear to be dose dependent
    • Kratom users may experience withdrawal with cessation
    • Management of kratom ingestion is supportive
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Methemoglobinemia in a 28-year-old woman treated with dapsone
  • Methemoglobinemia caused by sodium nitrite overdose
  • Fixed drug eruption
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Areas of Focus
    • Vulnerable populations
  • Topics
    • Addiction medicine
    • Drugs: pain (including opioids)

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire